🔓 Unlock the full profile of Gladys Dulay (Myovant Sciences), including verified contact details, financial insights, and professional associations.
See Gladys Dulay Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: gla*****@myo******.com
Mobile: 80139*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Gladys Dulay is currently the Founder & Managing Director of Gen2 BioVenture LLC, a role assumed on June 1, 2023, demonstrating entrepreneurial leadership in the biotechnology sector.
- Prior to founding Gen2 BioVenture LLC, Dulay served as Sr. Director of Medical Affairs Strategic Planning & Operations at Myovant Sciences from April 2022 to June 2023, focusing on oncology and women's health.
- Dulay held the position of Director of Medical Affairs Strategic Planning & Operations at Myovant Sciences from February 2020 to March 2022, contributing to strategic planning in critical therapeutic areas.
- From September 2020 to January 2021, Dulay participated in Business Alliance Management & Operations at Myovant Sciences, showcasing skills in partnership and operational effectiveness.
- At Johnson & Johnson Innovative Medicine, Dulay was Associate Director of Strategic Business Improvement from January 2017 to January 2020, playing a key role in enhancing business operations within the pulmonary hypertension segment.
- Dulay worked at Actelion as a Business Solutions Planning Consultant from January 2014 to January 2017, providing insights and strategic planning for rare diseases.
- Prior experience includes serving as a Project Management Consultant in Managed Care & Customer Operations at Genentech from January 2013 to January 2014, focusing on oncology and immunology, further enhancing expertise in biopharmaceutical operations.
- Myovant Sciences, established in 2016, operates in the healthcare industry, primarily focused on developing innovative therapies addressing women's health and prostate cancer, and trades publicly on NASDAQ under the symbol MYOV.
- As of the latest data, Myovant Sciences has a market capitalization of approximately $2.6 billion, indicating its significant position in the biotech market despite fluctuations in headcount over the past two years.